 Home > Biochemistry News > Biotechnology News > RNAi combined immunotherapy innovative combination therapy for hepatitis B is about to start phase 2 clinical trials

RNAi combined immunotherapy innovative combination therapy for hepatitis B is about to start phase 2 clinical trials

 Last Update: 2021-09-06
 Source: Internet
 Author: User

Tags

transcriptase

oxybutynin mechanism action

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Arbutus Biopharma and Vaccitech jointly announced that the two companies have reached a clinical trial cooperation agreement that will evaluate an immunotherapy combination consisting of RNAi therapy and immunotherapy for the treatment of standard nucleoside (acid) reversals.

Hepatitis B is a potentially life-threatening liver infection caused by HBV

AB-729 is a subcutaneous RNAi therapy that uses Arbutus' new covalently coupled N-acetylgalactosamine (GalNAc) delivery technology to target liver cells

VTP-300 is an immunotherapy with the mechanism of action very similar to that of vaccines

Note: The original text has been deleted

Reference materials:

[1] Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.